中国癌症杂志2024,Vol.34Issue(7) :695-701.DOI:10.19401/j.cnki.1007-3639.2024.07.009

鞘内注射治疗实体瘤脑膜转移的临床研究进展

Clinical research progress of intrathecal therapy in the treatment of leptomeningeal metastasis

黄思捷 康勋 李文斌
中国癌症杂志2024,Vol.34Issue(7) :695-701.DOI:10.19401/j.cnki.1007-3639.2024.07.009

鞘内注射治疗实体瘤脑膜转移的临床研究进展

Clinical research progress of intrathecal therapy in the treatment of leptomeningeal metastasis

黄思捷 1康勋 1李文斌1
扫码查看

作者信息

  • 1. 首都医科大学附属北京天坛医院神经肿瘤综合治疗中心,北京 100070
  • 折叠

摘要

脑膜转移(leptomeningeal metastasis,LM)是实体瘤患者的严重晚期并发症,常见于肺癌、乳腺癌及黑色素瘤患者中.近年来,由于诊断技术的进步,LM的诊出率逐渐上升.LM治疗的主要目标是维持患者的神经功能,改善生活质量,提高总生存率并延长无进展生存期.鞘内注射治疗是LM的主要治疗方法之一,能够直接将药物递送至蛛网膜下隙.传统的鞘内注射化疗药物包括甲氨蝶呤、阿糖胞苷及塞替哌等.随着新药研究的开展,多种化疗药物、靶向药物及免疫检查点抑制剂等也被尝试用于鞘内注射治疗.此外,不同的鞘内给药方式也给患者带来新希望.本文将对鞘内注射治疗LM的临床研究进展进行综述.

Abstract

Leptomeningeal metastasis(LM)is a serious late complication in patients with solid tumors,which is common in patients with lung cancer,breast cancer and melanoma.In recent years,due to the progress of diagnosis,the diagnosis rate of LM has gradually increased.The main goal of the therapy is to maintain neurological function,improve the quality of life and the overall survival rate,and prolong the progression-free survival time of patients.Intrathecal therapy is one of the main treatments for LM,which can deliver drugs directly to the subarachnoid space.The traditional intrathecal drugs are methotrexate,cytarabine and thiotepa.With the development of new research,a variety of chemotherapeutic drugs,targeted drugs and immune checkpoint inhibitors have also been used in intrathecal therapy.In addition,different ways of intrathecal administration also bring new hope to patients.This article reviewed the clinical research progress of intrathecal therapy in the treatment of LM.

关键词

脑膜转移/鞘内注射/化疗/靶向治疗/免疫治疗

Key words

Leptomeningeal metastasis/Intrathecal therapy/Chemotherapy/Targeted therapy/Immunotherapy

引用本文复制引用

基金项目

2020年国家和省级临床重点专科能力建设项目()

出版年

2024
中国癌症杂志
复旦大学附属肿瘤医院

中国癌症杂志

CSTPCDCSCD北大核心
影响因子:2.015
ISSN:1007-3639
参考文献量2
段落导航相关论文